Exploring new 5-Nitroimidazole Derivatives as Potent Acetylcholinesterase and Butyrylcholinesterase Enzyme Inhibitors

ArticleAçık Erişim

Özet

Discovering new compounds capable of inhibiting physiologically and metabolically significant drug targets or enzymes is of paramount importance in biological chemistry. With this aim, new 5-nitroimidazole derivatives (1–4) were designed and synthesized, and their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) were discovered using acetyl (butyryl) thiocholine and Ellman's reagents for spectrophotometric assay. The inhibitory profiles of the synthesized compounds were assessed by comparing their IC50 and Ki values. Results demonstrate significant inhibitory activity of all synthesized compounds against both AChE and BuChE compared to the reference compound, donepezil. Notably, compound 4 exhibited dual inhibition of these enzymes, showing the highest activity against Electrophorus electricus AChE (EeAChE) with a Ki value of 0.024±0.009 nM and against equine BuChE (eqBuChE) with a Ki value of 0.087±0.017 nM. Furthermore, molecular modeling was conducted to study the interaction modes of the most potent compound (4) and donepezil in the active site of their related enzymes’ crystal structures (PDB ID: 4EY7 and 4BDS, respectively). Additionally, drug-likeness, ADME, and toxicity profiles of the compounds and metronidazole were predicted. The above results indicated that the dual inhibition of these enzymes is considered as a promising strategy for the treatment of neurological disorder especially Alzheimer's disease. © 2024 Wiley-VHCA AG, Zurich, Switzerland.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/11035Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1002/cbdv.202400918Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorGursoy, Sule
dc.contributor.authorSatici, Doruk
dc.contributor.authorKuzu, Burak
dc.contributor.authorTurkmenoglu, Burcin
dc.contributor.authorDilek, Esra
dc.contributor.authorAlgul, Oztekin
dc.date.accessioned2026-10-18T20:26:08.431722559Z
dc.date.available2026-10-18T20:26:08.431722559Z
dc.date.issued2024
dc.description.abstractDiscovering new compounds capable of inhibiting physiologically and metabolically significant drug targets or enzymes is of paramount importance in biological chemistry. With this aim, new 5-nitroimidazole derivatives (1–4) were designed and synthesized, and their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) were discovered using acetyl (butyryl) thiocholine and Ellman's reagents for spectrophotometric assay. The inhibitory profiles of the synthesized compounds were assessed by comparing their IC50 and Ki values. Results demonstrate significant inhibitory activity of all synthesized compounds against both AChE and BuChE compared to the reference compound, donepezil. Notably, compound 4 exhibited dual inhibition of these enzymes, showing the highest activity against Electrophorus electricus AChE (EeAChE) with a Ki value of 0.024±0.009 nM and against equine BuChE (eqBuChE) with a Ki value of 0.087±0.017 nM. Furthermore, molecular modeling was conducted to study the interaction modes of the most potent compound (4) and donepezil in the active site of their related enzymes’ crystal structures (PDB ID: 4EY7 and 4BDS, respectively). Additionally, drug-likeness, ADME, and toxicity profiles of the compounds and metronidazole were predicted. The above results indicated that the dual inhibition of these enzymes is considered as a promising strategy for the treatment of neurological disorder especially Alzheimer's disease. © 2024 Wiley-VHCA AG, Zurich, Switzerland.
dc.description.sponsorshipFunding text 1: This study was funded by grants from Erzincan Binali Y\u0131ld\u0131r\u0131m University (grant number: TSA-2023-890). The authors would like to thank Erzincan Binali Y\u0131ld\u0131r\u0131m University, Basic Sciences Application and Research Center (EBYU-EUTAM) for the Schr\u00F6dinger Maestro 2021\u20132 program.; Funding text 2: This study was funded by grants from Erzincan Binali Y\u0131ld\u0131r\u0131m University (grant number: TSA\u20102023\u2010890). The authors would like to thank Erzincan Binali Y\u0131ld\u0131r\u0131m University, Basic Sciences Application and Research Center (EBYU\u2010EUTAM) for the Schr\u00F6dinger Maestro 2021\u20132 program.
dc.identifier.doi10.1002/cbdv.202400918
dc.identifier.eissn1612-1880
dc.identifier.issn1612-1872
dc.identifier.issue10
dc.identifier.pmid38924646
dc.identifier.scopus2-s2.0-85205119786
dc.identifier.startpagee202400918
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/11035
dc.identifier.volume21
dc.identifier.wosWOS:001340436700043
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofChemistry and Biodiversity
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject5-nitroimidazole
dc.subjectAcetylcholinesterase
dc.subjectAlzheimer's disease
dc.subjectButyrylcholinesterase
dc.subjectMolecular docking
dc.subjectAnimals
dc.subjectCholinesterase Inhibitors
dc.subjectDose-Response Relationship, Drug
dc.subjectElectrophorus
dc.subjectHorses
dc.subjectHumans
dc.subjectModels, Molecular
dc.subjectMolecular Docking Simulation
dc.subjectMolecular Structure
dc.subjectNitroimidazoles
dc.subjectStructure-Activity Relationship
dc.subject1 (2 methyl 5 nitro 1h imidazol 1 yl)propan 2 yl acetate
dc.subject1 (2 methyl 5 nitro 1h imidazol 1 yl)propan 2 yl cyclohexanecarboxylate
dc.subject2 (2 methyl 5 nitro 1h imidazol 1 yl)ethyl acetate
dc.subject2 (2 methyl 5 nitro 1h imidazol 1 yl)ethyl cyclohexanecarboxylate
dc.subject5 nitroimidazole derivative
dc.subject5,5' dithiobis(2 nitrobenzoic acid)
dc.subjectacetyl(butyryl)thiocholine
dc.subjectcholinesterase
dc.subjectcholinesterase inhibitor
dc.subjectdonepezil
dc.subjectmetronidazole
dc.subjectthiocholine
dc.subjectunclassified drug
dc.subject4-nitroimidazole
dc.titleExploring new 5-Nitroimidazole Derivatives as Potent Acetylcholinesterase and Butyrylcholinesterase Enzyme Inhibitors
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus9
rdl.citation.wos10
rdl.departmentDepartment of Biohemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Türkiye. | Department of Pharmaceutical Sciences, Institute of Health Sciences, Erzincan Binali Yıldırım University, Erzincan, Türkiye. | Department of Analytical Chemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Türkiye. | Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Türkiye.
rdl.oa.statusopen
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)